Plasmacytoma clinical trials
The registry lists 351 studies for Plasmacytoma across more than 10 countries. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-08-27.
Status
- Completed
- 244
- Terminated
- 56
- Status unknown
- 29
- Withdrawn
- 12
- Recruiting
- 4
- Not yet recruiting
- 3
Phase
- Phase 2
- 180
- Phase 1
- 103
- Phase 3
- 42
- Early Phase 1
- 4
- Phase 4
- 2
Where
- United States
- 296
- Canada
- 11
- United Kingdom
- 11
- China
- 8
- France
- 7
- Belgium
- 6
Who runs them
Mayo Clinic (26) · Fred Hutchinson Cancer Center (20) · Memorial Sloan Kettering Cancer Center (17) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15) · City of Hope Medical Center (11) · Barbara Ann Karmanos Cancer Institute (11) · Case Comprehensive Cancer Center (11) · Alliance for Clinical Trials in Oncology (11)
Studies
Recruiting first, then most recently updated. Showing 50 of 351 — search for more.
- Engineered Dendritic Cell Vaccines for Multiple MyelomaNot yet recruitingNCT06435910Phase 11 country
- Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNot yet recruitingNCT06429150Phase 1/21 country
- FAPI PET Imaging - An Exploratory StudyNot yet recruitingNCT07705074Phase 1/21 country
- The Indiana Myeloma RegistryRecruitingNCT036164831 country
- A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple MyelomaRecruitingNCT06717113Early Phase 11 country
- SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II TrialRecruitingNCT06863584Phase 21 country
- Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell TumorsRecruitingNCT04665076Not applicable1 country
- Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 24 countries
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 11 country
- A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 21 country
- Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02136134Phase 315 countries
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorCompletedNCT01350245Phase 21 country
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 21 country
- Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompletedNCT04080531Phase 41 country
- Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeCompletedNCT02921893Early Phase 11 country
- T-cell Receptor α/β Depleted Donor Lymphocyte InfusionTerminatedNCT05350163Phase 11 country
- MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable1 country
- Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic CancerCompletedNCT02184533Phase 11 country
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 11 country
- Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00019097Phase 21 country
- The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral FracturesCompletedNCT061535761 country
- Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 21 country
- Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 21 country
- Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple MyelomaCompletedNCT00049673Phase 31 country
- Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple MyelomaCompletedNCT00305812Phase 21 country
- Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaCompletedNCT00014508Phase 21 country
- High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00003353Phase 21 country
- Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell TransplantationTerminatedNCT00052884Phase 11 country
- Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00002878Phase 32 countries
- Activated White Blood Cells With ASCT for Newly Diagnosed Multiple MyelomaCompletedNCT00566098Phase 1/21 country
- Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaActive, not recruitingNCT02544308Phase 31 country
- Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 21 country
- Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00054158Phase 21 country
- Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or MyelomaCompletedNCT009000551 country
- Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaCompletedNCT01849783Phase 21 country
- Stereotactic Body Radiotherapy for the Treatment of Solitary Bone PlasmacytomaTerminatedNCT03312868Phase 21 country
- Collecting and Storing Blood Samples From Patients With CancerWithdrawnNCT00900120
- Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal MetastasesCompletedNCT00424242Early Phase 11 country
- Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple MyelomaCompletedNCT00792142Phase 21 country
- Phase I/II Study of hLL1 in Multiple MyelomaCompletedNCT00421525Phase 1/21 country
- High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicable1 country
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 21 country
- High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell TransplantTerminatedNCT00637767Phase 21 country
- Bone Marrow Transplant in Treating Patients With Hematologic CancersCompletedNCT00005797Phase 21 country
- Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT00612716Phase 21 country
- Arsenic Trioxide in Treating Patients With Multiple MyelomaTerminatedNCT00017433Phase 21 country
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple MyelomaTerminatedNCT00017069Phase 21 country
- Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicable1 country
- Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell TransplantCompletedNCT00534118Not applicable1 country
- Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple MyelomaCompletedNCT00084747Phase 1/21 country